Researchers from IBEC, in collaboration with an international team, describe the first molecules capable of regulate glycine receptors with light: Glyght and Azo-NZ1. The new molecules are a promising way to study neuronal circuits, to develop drug-based phototherapies non-invasively, and to understand neurological disorders related with the incorrect functioning of glycine receptors, as hyperekplexia, epilepsy and autism.
An international team led by SPECS Lab at the Institute for Bioengineering of Catalonia (IBEC) reveals how the brain improves through self-supervised learning combining an analysis of over three decades of research in neuroscience and artificial intelligence.
IBEC researchers led by Javier Ramón and Juan M. Fernández develop the first three-dimensional model for myotonic dystrophy, a rare disease that currently has no cure. The model combines patient cells and bioengineering techniques and represents a major advance over the use of animals and cell cultures. This new model will help in the design of personalized and more effective treatments, and for drug testing in a much more efficient way.
The accumulation of abnormal glycogen in glial cells of the nervous system causes inflammation and degeneration of the brain. The study, led by IRB Barcelona and with contribution of Arnau Hervera and Jose Antonio del Río from IBEC, has been recently published in the journal Brain.
Researchers at the Institute for Bioengineering of Catalonia (IBEC) led by Samuel Sánchez achieve a breakthrough in the field of biological robots by developing new biobots based on muscle cells that can swim at unprecedented velocities.
A comprehensive review led by IBEC researchers from the “Bacterial infections: antimicrobial therapies” group highlights the clinical relevance of the bacterium Pseudomonas aeruginosa and its presence in bacterial biofilms.
A team of researchers led by Raimon Jané from IBEC, together with international partners at imec in the Netherlands and a Hospital in Belgium, develops an innovative procedure to evaluate pulmonary diseases.
A team of researchers led by Samuel Sánchez from IBEC has monitored, for the first time, the behaviour of a swarm of nanorobots inside living mice. The study, published in the prestigious journal Science Robotics, reveals a coordinated movement, which could result in a very promising future in the field of precision medicine.
A study published in the journal eLife made all the possible mutations in the amyloid beta peptide and tested how they influence its aggregation into plaques, a pathological hallmark of Alzheimer’s disease.
A new study by IBEC’s Bacterial Infections: Antimicrobial Therapies and Molecular and cellular neurobiotechnology groups shows that Galleria mellonella larvae can be effective to test the toxicity of nanoparticles. This work thus paves the way toward a new animal model for toxicity studies that represent an inexpensive and more ethical alternative to rodent testing.